Temozolomide in glioblastoma treatment: 15-year clinical experience and analysis of its efficacy
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-2.14503Keywords:
chemotherapy, complex treatment, glioblastoma, temozolomideAbstract
Summary. Aim: To analyze retrospectively the efficacy of temozolomide (TMZ) in various treatment regimens in glioblastoma patients accounting for varying parameters of their treatment. Materials and Methods: 302 glioblastoma patients were treated at the State Institution “Romodanov Institute of Neurosurgery of the National Academy of Medical Sciences of Ukraine” from 2003 through 2017. All the patients were surgically treated. In 205 patients, the surgery was followed by adjuvant radiotherapy (RT) with concomitant TMZ (RT + TMZ group). In 97 patients, the surgery was followed by adjuvant RT only (RT group). Kaplan — Meier survival analysis with log-rank test and Cox proportional hazards regression analysis were used for comparing overall survival (OS) and recurrence-free survival (RFS) depending on the age and gender of the patients, the extent of tumor resection, the chemotherapy intensity and the type of RT. Results: In RT + TMZ group as a whole, OS median was 20.7 months vs 10.8 months in RT group (р < 0.0001). The RFS was 14.8 months vs 7.9 months, correspondingly (р < 0.0001).The survival did not depend on the age, gender or localization of the tumor. On the contrary, the intensity of CTX (the number of TMZ cycles in adjuvant mode), the extent of tumor resection, and the type of RT were among the factors affecting significantly OS and RFS. The improvement in OS and RFS with increasing number of the maintenance TMZ courses was more significant in the patients aged below 60. The use of stereotactic conformal mode for RT provides an advantage in the survival over the conventional RT in RT + TMZ group. Conclusions: The combination of concomitant and adjuvant maintenance CTX with TMZ was the most effective CTX regimen affecting positively OS and RFS.
References
GBD 2016 Brain and Other CNS Cancer Collaborators. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18: 376–93.
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023–75.
Ostrom QT, Gittleman H, Xu J, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol 2016; 18 (Suppl 5): 1–75.
Cenciarini M, Valentino M, Belia S, et al. Dexamethasone in glioblastoma multiforme therapy: mechanisms and controversies. Front Mol Neurosci 2019; 12: 65.
Wick W, Osswald M, Wick A, et al. Treatment of glioblastoma in adults. Ther Adv Neurol Disord 2018; 11: 1756286418790452.
Wang J, Hu G, Quan X. Analysis of the factors affecting the prognosis of glioma patients. Open Med (Wars) 2019; 14: 331–5.
Reifenberger G, Weber RG, Riehmer V, et al. German Glioma Network. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. Int J Cancer 2014; 135: 1822–31.
Hartmann C, Hentschel B, Simon M, et al. German Glioma Network. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 2013; 19: 5146–57.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–96.
Zhao YH, Wang ZF, Pan ZY, et al. A meta-analysis of survival outcomes following reoperation in recurrent glioblastoma: time to consider the timing of reoperation. Front Neurol 2019; 10: 286.
Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 2017; 18: e315–29.
Nabors LB, Portnow J, Ammirati M, et al. NCCN Guidelines Insights: Central nervous system cancers, Version 1.2017. J Natl Compr Canc Netw 2017; 15: 1331–45.
Sim HW, Morgan ER, Mason WP. Contemporary management of high-grade gliomas. CNS Oncol 2018; 7: 51–65.
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459–66.
Azoulay M, Shah J, Pollom E, et al. New hypofractionation radiation strategies for glioblastoma. Curr Oncol Rep 2017; 9: 58.
Bellera CA, MacGrogan G, Debled M, et al. Variables with time–varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer. BMC Med Res Methodol 2010; 10: 20.
Stupp R, Brada M, van den Bent MJ, et al. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25: iii 93–101.
Soni VS, Yanagihara TK. Tumor treating fields in the management of glioblastoma: opportunities for advanced imaging. Cancer Imaging 2019; 19: 76. https://doi.org/10.1186/s40644-019-0259-8.
Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 2017; 318: 2306–16.
Bhandari M, Gandhi AK, Devnani B, et al. Comparative study of adjuvant temozolomide six cycles versus extended 12 cycles in newly diagnosed glioblastoma multiforme. J Clin Diagn Res 2017; 11: XC04–8.
Sun H, Du S, Liao G, et al. Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis. Medicine 2015; 94: e827.
Alimohammadi E, Bagheri SR, Taheri S, et al. The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review. Oncol Rev 2020; 14: 461.
Jiapaer S, Furuta T, Tanaka S, et al. Potential strategies overcoming the temozolomide resistance for glioblastoma. Neurol Med Chir (Tokyo) 2018; 58: 405–21.
Brandes AA, Finocchiaro G, Zagonel V, et al. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro Oncol 2016; 18: 1304–12.
Wick W, Gorlia T, Bendszus M, et al. Lomustine and Bevacizumab in progressive glioblastoma. N Engl J Med 2017; 377: 1954–63.
Wick W, Weller M, van den Bent M, et al. MGMT testing–the challenges for biomarker-based glioma treatment. Nat Rev Neurol 2014; 10: 372–85.
Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1100–8.
Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis 2016; 3: 198–210.
Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013; 31: 4085–91.
Weiler M, Hartmann C, Wiewrodt D, et al. Phase II trial of radiochemotherapy with daily concomitant and adjuvant intensified (one week on/one week off) temozolomide plus indomethacin in newly diagnosed glioblastoma: UKT-05. Int J Rad Biol Phys 2010; 77: 670–6.
Gramatzki D, Kickingereder P, Hentschel B, et al. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology 2017; 88: 1422–30.
Jiang H, Zeng W, Ren X, et al. Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study. J Neurooncol 2019; 144: 127–35.
Garnier D, Meehan B, Kislinger T, et al. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. Neuro Oncol 2018; 20: 236–48.
Burić SS, Podolski-Renić A, Dinić J, et al. Modulation of antioxidant potential with coenzyme q10 suppressed invasion of temozolomide-resistant rat glioma in vitro and in vivo. Oxid Med Cell Longev 2019; 2019: 3061607.
Hermisson M, Klumpp A, Wick W, et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006; 96: 766–76.
Harat M, Blok M, Harat A, et al. The impact of adjuvant radiotherapy on molecular prognostic markers in gliomas. Onco Targets Ther 2019; 12: 2215–24.
Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765–73.
Madala HR, Punganuru SR, Arutla V, et al. Beyond brooding on oncometabolic havoc in IDH-mutant gliomas and AML: current and future therapeutic strategies. Cancers 2018; 10: 49.
Monica C, Jonathan D, Benoit M, et al. CNS immune privilege: hiding in plain sight. Immunol Rev 2006; 213: 48–65.
Britta E, Roxana C, Ingo B, et al. Vascular, glial, and lymphatic immune gate ways of the central nervous system. Acta Neuropathol 2016; 132: 317–38.
Hargadon K, Bullock T. The role of tumor/dendritic cell interactions in the regulation of anti-tumor immunity: the good, the bad, and the ugly. Front Immunol 2014; 5: 1–3.
Skachkova OV, Khranovska NM, Gorbach OI, et al. Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer. Exp Oncol 2013; 35: 109–13.
Liau LM, Ashkan K, Tran DD, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Translat Med 2018; 16: 142.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
